|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc. |
First Approval Date16 Mar 2010 |
/ Not yet recruitingNot Applicable Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients with Severe Hemophilia B
100 Clinical Results associated with Aptevo Europe Ltd.
0 Patents (Medical) associated with Aptevo Europe Ltd.
100 Deals associated with Aptevo Europe Ltd.
100 Translational Medicine associated with Aptevo Europe Ltd.